ArticlemedRxiv : the preprint server for health sciences2025
Demographic and Clinical Correlates of Discordant QuantiFERON TB Gold Tuberculosis Screening Results in a Low Endemicity Setting.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon-ɣ Release Assays (IGRAs), such as the QuantiFERON-TB Gold Plus (QFTTB) and T-SPOT.TB, are commonly used to detect prior exposure to Importance Statement: Reliable interpretation of interferon-γ release assays (IGRAs) is critical for the diagnosis and management of latent tuberculosis infection (LTBI). However, variability in test performance, particularly during serial or confirmatory testing, complicates clinical decision-making and may result in unnecessary treatment. Our study demonstrates that demographic factors, clinical comorbidities, and testing intervals contribute to discordant QuantiFERON-TB Gold Plus (QFTTB) results. These findings underscore the need to integrate epidemiologic risk, clinical history, and repeat testing before initiating therapy, especially in low-incidence regions where the pre-test probability of infection is low. Improved understanding of IGRA variability can strengthen both patient care and research applications, including TB vaccine and biomarker studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.